Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient

We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir loo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigirimana, Ferdinand, Van den Wijngaert, Sigi, Fosso, Christelle, Stoffels, Karolien, Martin, Charlotte, Maillart, Evelyne, Clevenbergh, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599868/
https://www.ncbi.nlm.nih.gov/pubmed/37886135
http://dx.doi.org/10.1155/2023/8865265
Descripción
Sumario:We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir looks promising in terms of safety and efficacy even in patients with end-stage renal disease awaiting renal transplant. Both drugs are first in class ARVs so that there is no cross resistance with previous drugs, maintaining their efficacy against MDR HIV.

Ejemplares similares